Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for CUROSURF
- Non Inferiority Trial Investigating Surfactants Administered Via MIST
- Prophylactic Minimally Invasive Surfactant Evaluation
- Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease
- Late Surfactant After a Recruitment Maneuver in Extremely Low Gestational Age Newborns - LATE-REC-SURF Trial
- Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19)
- Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19
- Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy
- Stress Assessment With and Without Analgesia During Surfactant Therapy in Preterm Infants.
- Caffeine Treatment in in the Delivery Room
- Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age
- Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.
- Intratracheal Budesonide/Surfactant Prevents BPD
- A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
- Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
- Does The Surfactant Administration by Aerosolization Effective?
- A Study in Preterm Neonates With RDS to Compare CUROSURF® Administration Through LISA and Conventional Administration
- Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With RDS
- A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
- Curosurf/Budesonide for Infants With Respiratory Distress Syndrome
- Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage
- A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants
- Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome
- High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant
- Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia
- Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
- Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks
- Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study
Clinical trials list
click for details